Technical Analysis for PULM - Pulmatrix, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
D | 1.83 | 1.98% | 0.04 |
PULM closed up 1.98 percent on Wednesday, May 15, 2024, on 75 percent of normal volume. It ran into resistance at its 50 day moving average. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
20 DMA Resistance | Bearish | 0.00% | |
50 DMA Resistance | Bearish | 0.00% | |
Gapped Up | Strength | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Stochastic Buy Signal | Bullish | 1.98% | |
Doji - Bullish? | Reversal | 1.98% | |
Lower Bollinger Band Touch | Weakness | 1.98% | |
Oversold Stochastic | Weakness | 1.98% | |
NR7 | Range Contraction | 2.81% | |
Earnings Movers | Other | 2.81% |
Alert | Time |
---|---|
10 DMA Support | about 15 hours ago |
50 DMA Support | about 15 hours ago |
Rose Above 50 DMA | about 15 hours ago |
Rose Above 10 DMA | about 15 hours ago |
Gapped Up (Full) | about 19 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/10/2024
Pulmatrix, Inc., a clinical stage biopharmaceutical company, engages in developing inhaled therapies to address serious pulmonary diseases using its iSPERSE technology. The company's proprietary product pipeline focuses on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with cystic fibrosis, as well as PUR1500, an inhaled product for the treatment of idiopathic pulmonary fibrosis. It is also developing PUR0200, a branded generic in clinical development for chronic obstructive pulmonary disease and other treatments. Pulmatrix, Inc. is based in Lexington, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Organ Systems Clinical Development Rare Diseases Chronic Obstructive Pulmonary Disease Idiopathic Pulmonary Fibrosis Cystic Fibrosis Pulmonary Disease Pulmonary Fibrosis Pulmonology Treatment Of Idiopathic Pulmonary Fibrosis Interstitial Lung Disease Pulmonary Rehabilitation
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Organ Systems Clinical Development Rare Diseases Chronic Obstructive Pulmonary Disease Idiopathic Pulmonary Fibrosis Cystic Fibrosis Pulmonary Disease Pulmonary Fibrosis Pulmonology Treatment Of Idiopathic Pulmonary Fibrosis Interstitial Lung Disease Pulmonary Rehabilitation
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 2.9103 |
52 Week Low | 1.55 |
Average Volume | 15,446 |
200-Day Moving Average | 1.99 |
50-Day Moving Average | 1.87 |
20-Day Moving Average | 1.92 |
10-Day Moving Average | 1.87 |
Average True Range | 0.13 |
RSI (14) | 44.75 |
ADX | 14.55 |
+DI | 23.46 |
-DI | 15.84 |
Chandelier Exit (Long, 3 ATRs) | 1.80 |
Chandelier Exit (Short, 3 ATRs) | 2.12 |
Upper Bollinger Bands | 2.11 |
Lower Bollinger Band | 1.74 |
Percent B (%b) | 0.24 |
BandWidth | 18.91 |
MACD Line | -0.03 |
MACD Signal Line | -0.01 |
MACD Histogram | -0.023 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 2.10 | ||||
Resistance 3 (R3) | 2.12 | 2.05 | 2.05 | ||
Resistance 2 (R2) | 2.05 | 1.98 | 2.04 | 2.04 | |
Resistance 1 (R1) | 1.94 | 1.94 | 1.91 | 1.92 | 2.02 |
Pivot Point | 1.87 | 1.87 | 1.85 | 1.86 | 1.87 |
Support 1 (S1) | 1.76 | 1.80 | 1.73 | 1.74 | 1.64 |
Support 2 (S2) | 1.69 | 1.76 | 1.68 | 1.62 | |
Support 3 (S3) | 1.58 | 1.69 | 1.61 | ||
Support 4 (S4) | 1.56 |